Moderna’s Next Shot: How the Pandemic Pioneer Is Building for the Future
Featuring Stéphane Bancel, CEO, Moderna
Interviewed by Amy Farley, Senior Editor, Fast Company
Moderna spent 10 years researching the once-novel use of mRNA in vaccines without a single product in the market—and then the pandemic hit, vaulting the company to a peak valuation of $196 billion. But with the worst of COVID-19 behind us, can Moderna prove it’s more than a one-shot wonder?